Relationship between ultrasound features of nonalcoholic fatty liver disease and cardiometabolic risk factors in patients with newly diagnosed type 2 diabetes

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 9, 2013, Pages 436-442

  Kosmalski, Marcin ^a   Kasznicki, Jacek ^a   Drzewoski, Józef ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Cardiovascular risk factors; Nonalcoholic fatty liver disease; Type 2 diabetes mellitus; Ultrasound examination

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CHOLESTEROL; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTHROPOMETRIC PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; BODY WEIGHT; CARDIOMETABOLIC RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; ENZYME ACTIVITY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLYCEMIC CONTROL; HIP CIRCUMFERENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; METABOLISM; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; LIPOPROTEINS, HDL; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PREVALENCE; RISK FACTORS;

EID: 84887250046     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.1919     Document Type: Article

References (36)

1. Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013; 1281: 106-122.
2. Ahmed MH, Barakat S, Almobarak AO. Nonalcoholic fatty liver disease and cardiovascular disease: has the time come for cardiologists to be hepatologists? J Obes. 2012; 2012: 483 135.
3. Saryusz-Wolska M, Szymańska-Garbacz E, Jablkowski M, et al. Rosiglitazone treatment in nondiabetic subjects with nonalcoholic fatty liver disease. Pol Arch Med Wewn. 2011; 121: 61-66.
4. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs. 2003; 63: 2379-2394.
5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med. 2001; 344: 495-500.
6. Janes CH, Lindor KD. Outcome of patients hospitalized for complications after outpatient liver biopsy. Ann Intern Med. 1993; 118: 96-98.
7. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007; 11: 37-54.
8. Poynard T, Ratziu V, Naveau S, et al. The diagnostic value of biomarkers (Steato Test) for the prediction of liver steatosis. Comp Hepatol. 2005; 4: 10.
9. Williams KH, Shackel NA, Gorrell MD, et al. Diabetes and Nonalcoholic Fatty Liver Disease: A Pathogenic Duo. Endocr Rev. 2013; 34: 84-129.
10. Guha IN, Parkers J, Roderick PR, et al. Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease. Gut. 2006; 55: 1650-1660.
11. Stepanova M, Younossi ZM. Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol. 2012; 10: 646-650.
12. World Health Organization: Definition and diagnosis of diabetes mellitus and intermediate hyperglicemia: report of a WHO/IDF Consultation. Geneva, World Health Org. 2006.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-419.
14. Meyers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol. 2009; 8: S25-33.
15. Hwang ST, Cho YK, Yun JW. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010; 40: 437-442.
16. Ziolkowski A, Wylezol M, Kukla M, et al. The comparison of scoring scales for liver biopsy assessment in morbidly obese patients undergoing bariatric Surgery. Obes Surg. 2005: 15; 1309-1314.
17. Lin YC, Lo HM, Chen JD. Sonographic fatty liver, overweight and ischemic heart disease. World J Gastroenterol. 2005; 11: 4838-4842.
18. Mirbagheri SA, Rashidi A, Abdi S, et al. Liver: an alarm for the heart? Liver Int. 2007; 27: 891-894.
19. Movahed MR, Sattur S, Hashemzadeh M. Independent association between type 2 diabetes mellitus and hypertension over a period of 10 years in a large inpatient population. Clin Exp Hypertens. 2010; 32: 198-201.
20. Goland S, Shimoni S, Zornitzki T, et al. Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol. 2006; 40: 949-955.
21. Hamaguchi M, Kojima T, Takeda N, et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol. 2007; 13: 1579-1584.
22. Juárez-Rojas JG, Medina-Urrutia AX, Jorge-Galarza E, et al. Fatty Liver Increases the Association of Metabolic Syndrome With Diabetes and Atherosclerosis. Diabetes Care. 2013; 36: 1726-1728.
23. Sehested TS, Hansen TW, Olsen MH. Measures of overweight and obesity and risk of cardiovascular disease: a population-based study. Eur J Cardiovasc Prev Rehabil. 2010; 17: 486-490.
24. Tergher G, Bertolini L, Padovani R. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007; 30: 1212-1218.
25. Zhang Y, Lu X, Hong J, et al. Positive correlations of liver enzymes with metabolic syndrome including insulin resistance in newly diagnosed type 2 diabetes mellitus. Endocrine. 2010; 38: 181-187.
26. Yun KE, Shin CY, Yoon YS, Park HS. Elevated alanine aminotransferase levels predict mortality from cardiovascular disease and diabetes in Koreans. Atherosclerosis. 2009; 205: 533-537.
27. Seo JA, Kim NH, Park SY, et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease. Clin Endocrinol (Oxf). 2008; 68: 555-560.
28. Jung DH, Lee YJ, Ahn HY, et al. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med. 2010; 48: 1829-1834.
29. Tahan V, Canbakan B, Balci H, et al. Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk. Hepatogastroenterology. 2008; 55: 1433-1438.
30. Franchini M, Targher G, Lippi G. Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons? Adv Clin Chem. 2010; 50: 47-63.
31. Neuman G, Sagi R, Shalitin S, et al. Serum inflammatory markers in overweight children and adolescents with non-alcoholic fatty liver disease. Isr Med Assoc J. 2010; 12: 410-415.
32. Oruc N, Ozutemiz O, Yuce G, et al. Serum procalcitonin and CRP levels in non-alcoholic fatty liver disease: a case control study. BMC Gastroenterol. 2009; 9: 16.
33. Hwang ST, Cho YK, Yun JW. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010; 40: 437-442.
34. Bhatt KN, Wells BJ, Sperling LS, Baer JT. High-density lipoprotein therapy: is there hope? Curr Treat Options Cardiovasc Med. 2010; 12: 315-328.
35. Merat S, Yarahmadi S, Tahaghoghi S, et al. Prevalence of fatty liver disease among type 2 diabetes mellitus patients and its relation to insulin resistance. Middle East Journal of Digestive Disease. 2009; 1: 74-79.
36. Lee YJ, Lee HR, Lee JH, et al. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults. Clin Chem Lab Med. 2010; 48: 175-180.